MDI-0151 (MOD-A)
Neutrophil-driven inflammatory diseases (e.g., ANCA-associated vasculitis, COPD)
PreclinicalActive
Key Facts
Indication
Neutrophil-driven inflammatory diseases (e.g., ANCA-associated vasculitis, COPD)
Phase
Preclinical
Status
Active
Company
About Alivexis
Alivexis develops novel small-molecule drugs for cancer and inflammatory diseases using its proprietary computational drug discovery platform.
View full company profile